Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
8.30
-0.38 (-4.38%)
At close: Oct 9, 2025, 4:00 PM EDT
8.45
+0.15 (1.81%)
After-hours: Oct 9, 2025, 7:33 PM EDT
Alvotech Revenue
Alvotech had revenue of $173.34M in the quarter ending June 30, 2025, a decrease of -12.79%. This brings the company's revenue in the last twelve months to $562.48M, up 82.19% year-over-year. In the year 2024, Alvotech had annual revenue of $491.98M with 426.84% growth.
Revenue (ttm)
$562.48M
Revenue Growth
+82.19%
P/S Ratio
4.20
Revenue / Employee
$555,808
Employees
1,012
Market Cap
2.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 491.98M | 398.60M | 426.84% |
| Dec 31, 2023 | 93.38M | 8.37M | 9.84% |
| Dec 31, 2022 | 85.02M | 45.33M | 114.23% |
| Dec 31, 2021 | 39.68M | -29.77M | -42.86% |
| Dec 31, 2020 | 69.45M | -13.23M | -16.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ALVO News
- 3 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 3 days ago - European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency - GlobeNewsWire
- 17 days ago - European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva® - GlobeNewsWire
- 17 days ago - European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner - GlobeNewsWire
- 20 days ago - Alvotech Announces Marketing Approval in Japan of Three New Biosimilars - GlobeNewsWire
- 4 weeks ago - Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York - GlobeNewsWire
- 7 weeks ago - Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea® - GlobeNewsWire